Biophytis 과거 수익 실적

과거 기준 확인 0/6

Biophytis의 연간 평균 수익은 2.6%였으며, Biotechs 산업의 수익은 연간 증가했습니다(7.7%).

주요 정보

2.6%

수익 성장률

60.7%

EPS 성장률

Biotechs 산업 성장	30.8%
매출 성장률	n/a
자기자본 수익률	n/a
순이익	n/a
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

업데이트 없음

Recent updates

Biophytis (EPA:ALBPS) Has Debt But No Earnings; Should You Worry?

Nov 18

수익 및 비용 분석

Biophytis 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

ENXTPA:ALBPS 수익, 비용 및 수입 (EUR Millions )
날짜	수익	G+A 비용	R&D 비용
30 Jun 24	-15	5	7
31 Mar 24	-16	5	8
31 Dec 23	-17	5	9
30 Sep 23	-18	5	11
30 Jun 23	-20	5	13
31 Mar 23	-22	6	14
31 Dec 22	-24	7	16
30 Sep 22	-27	8	17
30 Jun 22	-30	9	19
31 Mar 22	-31	8	19
31 Dec 21	-31	7	20
30 Sep 21	-28	6	16
30 Jun 21	-25	5	12
31 Mar 21	-25	4	11
31 Dec 20	-26	4	10
30 Sep 20	-24	4	10
30 Jun 20	-22	4	9
31 Mar 20	-22	6	9
31 Dec 19	-19	7	9
30 Sep 19	-19	7	10
30 Jun 19	-18	8	10
31 Mar 19	-15	5	10
31 Dec 18	-14	4	10
30 Sep 18	-13	4	9
30 Jun 18	-12	3	8
31 Mar 18	-12	3	8
31 Dec 17	-11	3	7
30 Sep 17	-10	3	6
30 Jun 17	-9	3	6
31 Mar 17	-9	3	5
31 Dec 16	-8	3	5
30 Sep 16	-8	3	4
30 Jun 16	-7	3	4
31 Mar 16	-6	3	3
31 Dec 15	-5	3	2
30 Sep 15	-4	2	1
30 Jun 15	-2	1	1
31 Mar 15	-1	1	0
31 Dec 14	-1	0	0

양질의 수익: ALBPS 은(는) 현재 수익성이 없습니다.

이익 마진 증가: ALBPS 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: ALBPS 은(는) 수익성이 없지만 지난 5년 동안 연간 2.6% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 ALBPS 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: ALBPS 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -18.2% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: ALBPS 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

Biophytis 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Recent updates

Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity

Biophytis S.A., Annual General Meeting, Jun 24, 2024

Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity

Biophytis S.A.(OTCPK:BPTS.Y) dropped from NASDAQ Composite Index

Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity

Biophytis SA Launches OBA Phase 2 Clinical Study in Obesity with BIO101 (20-Hydroxyecdysone)

Biophytis S.A., Annual General Meeting, Mar 18, 2024

Biophytis S.A. Announces the Publication of the Results of its COVA Phase 2-3 Study in eClinicalMedicine, Part of The Lancet

Biophytis S.A. and the University of Li Ge Explore the Potential of Sarconeos (BIO101) in the Treatment of Viral Respiratory Diseases

Biophytis S.A. Appoints Yann Meunier and Bernard L vy to its Scientific Advisory Board

Biophytis Receives Notice of Delisting from Nasdaq and Announces It Will Request A Hearing Before the Nasdaq Hearings Panel

Biophytis S.A. Provides an Update on the Progress of its R&D Projects over the 1St Half of the Year and the Last Few Months

Biophytis SA Provides Update on its Early Access Programs for Sarconeos (BIO101) in Treatment of Severe Forms of COVID-19

Biophytis SA Receives Response from the French National Authority for Health to Request for Early Access Authorization in France for Patients Suffering from Severe Forms of COVID-19

Biophytis S.A. Announces Executive Changes

Biophytis Obtains Fda Authorization to Initiate the Sara-31 Phase 3 Study in Sarcopenia

Biophytis SA Announces Next Regulatory Steps in Europe and the United States for its COVA Project

Biophytis SA Receives Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe

Biophytis S.A. Files for a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19

Biophytis and Seqens Sign A Partnership to Produce Sarconeos (Bio101) Active Compound

Biophytis SA Filed with the FDA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia

Biophytis SA Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress

Biophytis S.A., Annual General Meeting, Jun 16, 2023

Biophytis S.A. has completed a Follow-on Equity Offering in the amount of €2.302535 million.

Biophytis SA Files for Pre-Submission Meeting Request with the European Medicine Agency (EMA) to Discuss Filing for Conditional Marketing Authorisation (CMA) in Europe

Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19

Biophytis S.A. Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd

Biophytis to Take Appropriate Measures After Receiving Nasdaq Deficiency Notice

Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19

Biophytis Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

Biophytis S.A. Announces Promising Top Line Results of Its Phase 2-3 Cova Clinical Study in COVID-19-Related Respiratory Failure

Biophytis SA to Update on the Development of Sarconeos (BIO101) in Covid-19 at 4th Annual Longevity Therapeutics Summit

Biophytis Presents the Development of Sarconeos in Phase 3 for the Treatment of Sarcopenia At the 15th SCWD International Congress

Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), A Rare Neuromuscular Disease

Biophytis SA, Annual General Meeting, Jun 03, 2022

Biophytis SA Announces Chief Financial Officer Changes

Biophytis Sa Receives Approval from the ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients Through an Expanded Access Program

Biophytis SA to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3

Biophytis (EPA:ALBPS) Has Debt But No Earnings; Should You Worry?

Biophytis to Present Full Results from the Sara-INT Phase 2B Trial of Sarconeos in Sarcopenia At the 11Th Annual International Conference

Biophytis SA Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 Cova Study with Sarconeos (Bio101) in Covid-19

Biophytis SA Receives Favorable Recommendation from Data Monitoring Committee Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the Cova Study in COVID-19

Independent Director Jean Franchi has left the company

Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

Biophytis SA to Release Topline Results for SARA-INT Phase 2 Study in August 2021

Biophytis SA Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study

BIOPHYTIS Completes Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the Second Interim Analysis

Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021

Biophytis SA, Annual General Meeting, Apr 26, 2021

Biophytis Sa Announces That Patient Recruitment Will Begin in France and Belgium for Part 2 of Its Cova Study Assessing Sarconeos

New 90-day high: €1.69

Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial

Biophytis SA Receives DMC Recommendation for Starting Recruitment for Part 2 of Its Phase 2-3 Cova Study in COVID-19

New 90-day high: €1.32

New 90-day high: €0.74

New 90-day high: €0.71

Biophytis Enrolls First Patient in Brazil in COVA, A Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure

New 90-day low: €0.39

New 90-day low: €0.51

New 90-day low - €0.62

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기